Roth Capital initiated coverage of Pelthos Therapeutics (PTHS) with a Buy rating and $57 price target The firm sees growing revenue for the company from the Zelsuvmi launch underway and Xepi in late 2026. Pelthos should see momentum in molluscum contagiosum and impetigo, respectively, files to sell common stock, no amount given
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTHS:
- Pelthos Therapeutics price target raised to $57 from $50 at Oppenheimer
- Pelthos Therapeutics price target raised to $75 from $60 at Alliance Global
- Pelthos Therapeutics Reports Promising Q3 2025 Results
- Pelthos Therapeutics Earnings Call Highlights Growth and Challenges
- Pelthos Therapeutics Reports Q3 2025 Financial Results